An Observational Pregnancy Safety Study in Women with Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® (inebilizumab-cdon) during Pregnancy (VIB0551.P4.S4 /20230064)

First published 29/06/2023

Last updated 02/04/2025

EU PAS number:

EUPAS105613

Study

Ongoing

Documents

Study protocol

Updated protocol

Protocol-Published Original inebilizumab-cdon 20230064 .pdf

First published: 14/03/2025

English (452.31 KB - PDF)View document

Study results

Study report

Other information

Secondary tabs